2025 Canada Guide: Top 5 Osteoarthritis Disease-Modifying Agents for Dogs — Clinician-Reviewed Options (Adequan, Cartrophen, Legend, Librela, Solensia) — Which Is Right for Your Dog?
This category covers prescription disease-modifying osteoarthritis (OA) drugs and biologic agents for dogs intended to slow joint degeneration and reduce inflammation. It includes polysulfated glycosaminoglycans (e.g., Adequan Canine), pentosan-type agents (e.g., Cartrophen Vet), hyaluronic acid injectables (represented here by Legend Injectable Solution as an example of the class), and newer regenerative/biologic therapies such as anti-nerve growth factor monoclonal antibodies (Librela and Solensia). These products are typically used as part of a multimodal OA management plan alongside NSAIDs, weight management, physical therapy, and joint supplements. In Canada, pet owners and veterinarians increasingly choose these prescription options because they target underlying joint health, can reduce reliance on daily oral medications, and—when combined with rehabilitation—can meaningfully improve mobility and quality of life for aging or arthritic dogs. Key consumer preferences driving demand include evidence of clinical benefit, convenience of dosing, perceived safety compared with long-term NSAID use, and access through licensed veterinarians or authorized clinics.
Inception's AI took the time to understand this market in Canada · We may earn a commission on purchases. It never affects our rankings.
Top Picks Summary
Adequan Canine
Adequan Canine (polysulfated glycosaminoglycan) is a long-established injectable disease-modifying agent that supports cartilage matrix production and joint health, earning its place as a market staple because of decades of clinical use and a broad veterinary familiarity. Compared with newer biologics on this list, Adequan is typically more cost-effective per treatment course and is often chosen as a first-line prescription option for owners seeking a time-tested, clinic-administered therapy rather than higher-cost monthly monoclonal antibodies.
Cartrophen Vet
Cartrophen Vet (pentosan polysulfate) is recognized for its anti-inflammatory and potential disease-modifying effects on canine joints, offering a relatively short injectable course that can reduce clinical signs and slow progression. Financially it often sits between older PSGAGs like Adequan and premium biologics, making it an attractive middle-ground option for practices and owners seeking stronger disease-modifying action than basic chondroprotectants without the higher recurring cost of monthly mAbs.
Legend Injectable Solution
Legend (sodium hyaluronate) provides intra-articular or injectable hyaluronic supplementation to improve joint lubrication and shock absorption, and is valued as an adjunctive, technically simple therapy that can complement systemic agents. Compared with systemic PSGAGs or pentosan products it is often used in targeted joint therapy and can reduce the need for more frequent systemic dosing, offering clinics a lower-cost, procedure-driven option for focal osteoarthritis management.
Librela
Librela (bedinvetmab) is a targeted anti-nerve growth factor monoclonal antibody that delivers rapid, meaningful pain relief with once-monthly subcutaneous dosing, positioning it as a clinical leader for symptomatic control in canine osteoarthritis. Technically more advanced than traditional disease-modifying injectables, Librela commands a premium price but can reduce concurrent analgesic needs and improve quality of life quickly, making it cost-justifiable for patients where fast functional gain is prioritized.
Solensia
Solensia (frunevetmab) is another anti-NGF monoclonal antibody option that provides monthly targeted analgesia and is considered a market leader for pet owners seeking biologic, non-opioid pain control; it competes directly with other mAbs by differentiating on safety data and administration convenience. Although it represents the higher end of prescription pricing, Solensia’s technical advantage is its mechanism-specific approach that can be used when traditional disease-modifying injectables like Adequan or Cartrophen offer insufficient symptomatic relief.
What the Research Says — Beginner-Friendly Evidence Overview
Scientific studies and clinical trials have evaluated disease-modifying approaches for canine OA across several classes of products. While results vary by product and patient population, the body of evidence supports that certain polysulfated glycosaminoglycans, pentosan-type agents, hyaluronic acid injections, and anti-NGF monoclonal antibodies can reduce pain and improve mobility when used as part of a comprehensive treatment plan. Veterinarians weigh efficacy data together with safety profiles and practical considerations (cost, dosing schedule, and availability) when recommending a product for an individual dog.
Polysulfated glycosaminoglycans (e.g., Adequan Canine) — Randomized controlled trials and clinical reports indicate reduced lameness scores and improved joint function for some dogs, with a favorable safety profile when used as directed.
Pentosan-type polysaccharides (e.g., Cartrophen Vet) — Evidence shows anti-inflammatory effects and potential improvement in cartilage metabolism and pain scores; used widely in veterinary practice with periodic injections.
Hyaluronic acid injections (class example: Legend Injectable Solution) — Intra-articular or peri-articular hyaluronate reduces joint friction and can lower inflammation; studies and clinical experience support short- to medium-term improvements in mobility.
Anti-NGF monoclonal antibodies (Librela, Solensia) — Clinical trials demonstrate clinically meaningful reductions in pain and improved activity in many dogs, with convenient dosing intervals and a mechanism that directly targets pain signaling.
Multimodal context — Systematic reviews and consensus guidelines emphasize combining disease-modifying agents with NSAIDs (when needed), weight management, rehabilitation, and supplements for best outcomes.
Safety and monitoring — Research highlights the importance of veterinary supervision: baseline exams, periodic rechecks, and tailored plans are recommended to monitor response and adverse effects.
Frequently Asked Questions
Which OA drug should I choose for my dog?
Adequan Canine is a strong fit for many dogs because it’s a polysulfated glycosaminoglycan (PSGAG) injectable “market staple” with a 4.3 average rating and a typical series (initial then monthly maintenance) under veterinary guidance.
What does Cartrophen Vet do for canine joints?
Cartrophen Vet is a pentosan polysulfate sodium injectable meant to reduce inflammation and support joint function, with disease-modifying effects reported to improve the synovial fluid and cartilage environment; it’s usually given weekly at first per vet protocol.
How do prices compare between Adequan Canine and Cartrophen Vet?
Price isn’t provided for Adequan Canine or Cartrophen Vet in the available data, so I can’t compare Canadian costs; what we do know is Adequan Canine has a 4.3 rating and Cartrophen Vet has a 4.1 rating.
Is Legend Injectable Solution a systemic OA treatment?
Legend Injectable Solution is sodium hyaluronate (hyaluronic acid) injectable intended to improve synovial fluid viscosity and lubrication, and it’s commonly used as an adjunct to multimodal osteoarthritis management to reduce pain and improve mobility; rating is 3.6.
Conclusion
In Canada, veterinarians commonly integrate prescription disease-modifying agents with lifestyle and rehabilitative strategies to slow OA progression and improve comfort. The five products highlighted here — Adequan Canine, Cartrophen Vet, Legend Injectable Solution, Librela, and Solensia — represent the main classes available through veterinary prescription. For many patients seeking rapid pain relief with convenient dosing and a favorable safety profile, anti-NGF monoclonal antibodies like Librela and Solensia are frequently recommended; Librela is often chosen in clinics for its demonstrated clinical benefits and practical dosing schedule. That said, Adequan Canine, Cartrophen Vet, and hyaluronic acid options also remain valuable components of multimodal care depending on the dog’s condition and treatment goals. We hope this guide helped you find relevant options — refine or expand your search using the site search or consult your veterinarian to identify the best prescription plan for your dog.